Edition:
United States

Cytokinetics Inc (CYTK.OQ)

CYTK.OQ on NASDAQ Stock Exchange Global Select Market

14.05USD
24 May 2017
Change (% chg)

$0.05 (+0.36%)
Prev Close
$14.00
Open
$14.00
Day's High
$14.10
Day's Low
$13.85
Volume
98,006
Avg. Vol
179,322
52-wk High
$17.20
52-wk Low
$7.77

CYTK.OQ

Chart for CYTK.OQ

About

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development... (more)

Overall

Beta: 1.72
Market Cap(Mil.): $681.48
Shares Outstanding(Mil.): 48.68
Dividend: --
Yield (%): --

Financials

  CYTK.OQ Industry Sector
P/E (TTM): 647.25 141.11 17.36
EPS (TTM): 0.02 -- --
ROI: 1.92 2.25 -5.72
ROE: 3.97 0.17 -5.10

BRIEF-Cytokinetics announces orphan drug designation for CK-2127107 for treatment of spinal muscular atrophy

* Cytokinetics announces orphan drug designation for CK-2127107 for the treatment of spinal muscular atrophy

May 15 2017

BRIEF-Cytokinetics announces results from dose escalation phase of Cosmic-HF

* Cytokinetics announces results from dose escalation Phase of Cosmic-HF

May 01 2017

BRIEF-Cytokinetics Q1 loss per share $0.62

* Cytokinetics, inc. Reports first quarter 2017 financial results

Apr 27 2017

BRIEF-Cytokinetics announces start of second cohort in Phase 2 clinical trial of CK-2127107

* Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy Source text for Eikon: Further company coverage:

Mar 29 2017

BRIEF-Cytokinetics and Origent Data Sciences report advancement of research collaboration

* Cytokinetics - co, Origent Data Sciences announced advancement of their research collaboration

Mar 23 2017

BRIEF-Cytokinetics announces preclinical data for CK-2127107 presented at MDA Scientific Conference

* Cytokinetics announces preclinical data for CK-2127107 presented at MDA Scientific Conference

Mar 22 2017

BRIEF-Cytokinetics Q4 EPS $0.16

* Cytokinetics, inc. Reports fourth quarter 2016 financial results

Feb 16 2017

BRIEF-Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil

* Cytokinetics and Royalty Pharma announce $100 million transaction for Omecamtiv Mecarbil

Feb 02 2017

More From Around the Web

Earnings vs. Estimates